Back to Agenda
Drug Repurposing: Opportunities & Challenges
Session Chair(s)
Tamara Di Carlantonio, MA
Regulatory Policy Lead
Roche, Switzerland
Drug repurposing is regarded as a potential solution to treatment gaps and increasing healthcare costs, especially after COVID. However, this complex topic grants deeper discussion and a collaborative, multi-stakeholder approach.
Learning Objective : • Uncover the different aspects that come to play in drug repurposing: (including but not limited to) scientific, regulatory, patient access, healthcare systems, commercial • Articulate areas where repurposing presents opportunities • Describe current and potential challenges • Discuss how to tackle challenges in order to realize opportunities
Speaker(s)
![Alberto Ganan Jimenez, PhD](/_Images/member/Generic_Image_Missing-Profile.jpg)
EMA Repurposing Pilot
Alberto Ganan Jimenez, PhD
European Medicines Agency, Netherlands
Head of Committees and Quality Assurance
Donald Lo, PhD
EATRIS, Netherlands
Director of Medicines Development
![Guillaume Canaud](/_Images/member/Generic_Image_Missing-Profile.jpg)
Targeted Therapy in PIK3CA-Related Overgrowth Syndrome
Guillaume Canaud
Neckar Enfants Malades Hospital, France
Chief of the Overgrowth Syndromes and Vascular anomalies Unit
Drug Repurposing: How to Proceed?
François Houyez
European Organisation for Rare Diseases (EURORDIS), France
Treatment Information and Access Director, Health Policy Advisor
Panelist
Solange Corriol-Rohou, DrMed, MD, PhD
AstraZeneca , France
Senior Director, Global Regulatory Affairs & Policy, R&D, Europe
Panelist
Sini Eskola, MPharm, MS, MSc
EFPIA - European Federation of Pharmaceutical Industries and Associations, Belgium
Director Regulatory Strategy
Have an account?